Q2 EPS Estimates for Viridian Therapeutics Raised by Wedbush

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities researchers at Wedbush increased their Q2 2025 EPS estimates for Viridian Therapeutics in a research note issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.82) per share for the quarter, up from their previous forecast of ($1.04). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.25) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($3.10) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at $5.43 EPS and FY2029 earnings at $8.81 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.08. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business’s quarterly revenue was up .0% on a year-over-year basis.

A number of other equities research analysts have also recently commented on the company. Royal Bank of Canada cut their price target on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday. Needham & Company LLC dropped their target price on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. The Goldman Sachs Group dropped their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, JMP Securities decreased their target price on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.70.

Viridian Therapeutics Stock Performance

Shares of Viridian Therapeutics stock opened at $12.54 on Friday. The firm has a market capitalization of $1.02 billion, a P/E ratio of -2.91 and a beta of 0.57. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The business’s fifty day simple moving average is $13.71 and its 200 day simple moving average is $17.49. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $27.20.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new position in Viridian Therapeutics during the fourth quarter valued at approximately $26,000. Amalgamated Bank increased its holdings in shares of Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after purchasing an additional 840 shares during the period. Foresite Capital Management VI LLC purchased a new stake in shares of Viridian Therapeutics in the fourth quarter worth $38,000. AlphaQuest LLC boosted its stake in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after buying an additional 1,519 shares during the period. Finally, GAMMA Investing LLC increased its stake in Viridian Therapeutics by 3,892.9% in the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after acquiring an additional 8,214 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.